CO5590904A2 - Esteriodes 3-nitrogen-6,7-dioxigeno y usos relacionados con este - Google Patents
Esteriodes 3-nitrogen-6,7-dioxigeno y usos relacionados con esteInfo
- Publication number
- CO5590904A2 CO5590904A2 CO02106292A CO02106292A CO5590904A2 CO 5590904 A2 CO5590904 A2 CO 5590904A2 CO 02106292 A CO02106292 A CO 02106292A CO 02106292 A CO02106292 A CO 02106292A CO 5590904 A2 CO5590904 A2 CO 5590904A2
- Authority
- CO
- Colombia
- Prior art keywords
- carbons
- groups
- nitrogen
- oxygen
- numerals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0063—Nitrogen and oxygen at position 2(3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un compuesto de fórmula y su sales, solvatos, esteroisómeros y prodrogas farmacéuticamente aceptables en aislados o en mezcla, endonde independientemente en cada ocurrencia:R1 y R2 se selecciona de hidrógeno, oxígeno con el fin de formar grupos nitro u oxima, amino, -SO3-R, y grupos orgánicos que tienen de 1 a 30 carbonos y opcionalmente que contienen 1-6 heteroátomos seleccionados de nitrógeno, oxígeno, fósforo, silicio, y azufre, donde R2 puede ser un enlace directo al numeral 3 o R1 y R2 pueden, junto con el N al cual ellos están los dos unidos, formar una estructura heterocíclica que puede ser parte de un grupo orgánico que tiene de 1 a 30 carbonos y opcionalmente que contiene 1-6 heteroátomos seleccionados de nitrógeno, oxígeno y silicio; y en donde R1 puede ser una cadena de 2, o 3 átomos al numeral 2 de tal forma que -N-R1- forma parte de la estructura bicíclica fusionada al anillo A;R3 y R4 se seleccionan de enlaces directos a 6 y 7 respectivamente con el fin de formar grupos carbonilo, hidrógeno, o grupos protectores tales que R3 y/o R4 es parte del grupo protector hidroxilo o carbonilo;Los numerales 1 hasta 17 representan cada uno un carbono, en donde los carbonos de los numerales 1, 2, 4, 11, 12, 15, 16 y 17 pueden ser independientemente sustituidos conuno de: =O, =C(R5) (R5), =C=C (R5) (R5), -C(R5) (R5) (C(R5) (R5))n- y - (O(C(R5) (R5))nO)- en donde los rasgos van desde 1 hasta aproximadamente 6; o dos de los siguientes, que son independientemente seleccionados: -X, -N(R1)(R2), -R5 o -OR6; y donde los carbonos en los numerales 5, 8, 9, 10, 13 y 14 pueden ser independientemente sustituidos con uno de -X, -R5, -N(R1) (R2) o -OR6;además de los grupos -OR3 y -OR4 como se muestran,cada uno de los carbonos 6 y 7 pueden ser independientemente sustituidos con uno -X, -N(R1) (R2), -R5 o -OR6; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20061700P | 2000-04-28 | 2000-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5590904A2 true CO5590904A2 (es) | 2005-12-30 |
Family
ID=22742458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO02106292A CO5590904A2 (es) | 2000-04-28 | 2002-11-22 | Esteriodes 3-nitrogen-6,7-dioxigeno y usos relacionados con este |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US6635629B2 (es) |
| EP (1) | EP1278763B1 (es) |
| JP (1) | JP2003531916A (es) |
| KR (1) | KR20030045671A (es) |
| CN (1) | CN1214039C (es) |
| AP (1) | AP1825A (es) |
| AT (1) | ATE353909T1 (es) |
| AU (2) | AU5208401A (es) |
| BG (1) | BG107289A (es) |
| BR (1) | BR0110419A (es) |
| CA (1) | CA2418748A1 (es) |
| CO (1) | CO5590904A2 (es) |
| DE (1) | DE60126597T2 (es) |
| DK (1) | DK1278763T3 (es) |
| DZ (1) | DZ3355A1 (es) |
| EE (1) | EE200200613A (es) |
| ES (1) | ES2282247T3 (es) |
| HK (1) | HK1050694A1 (es) |
| HR (1) | HRP20020944A2 (es) |
| HU (1) | HUP0300908A2 (es) |
| IL (2) | IL152448A0 (es) |
| MA (1) | MA25808A1 (es) |
| MX (1) | MXPA02010645A (es) |
| NO (1) | NO324873B1 (es) |
| NZ (1) | NZ522181A (es) |
| OA (1) | OA12255A (es) |
| PL (1) | PL365798A1 (es) |
| PT (1) | PT1278763E (es) |
| RU (1) | RU2291873C2 (es) |
| SK (1) | SK15692002A3 (es) |
| UA (1) | UA79229C2 (es) |
| WO (1) | WO2001083512A1 (es) |
| YU (1) | YU88102A (es) |
| ZA (1) | ZA200208631B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| DZ3355A1 (fr) * | 2000-04-28 | 2001-11-08 | Inflazyme Pharm Ltd | Steroides 3-azote-6,7-dioxyde et les emplois qui s'y rapportent |
| WO2002085296A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| MXPA03010585A (es) | 2001-05-22 | 2004-04-02 | Inflazyme Pharm Ltd | Mejoras del proceso en quimica de esteroide. |
| CA2480427C (en) | 2002-08-01 | 2010-08-31 | Yamanouchi Pharmaceutical Co., Ltd. | Novel potassium-dependent sodium-calcium exchanger |
| US20050101545A1 (en) * | 2003-07-31 | 2005-05-12 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050113318A1 (en) * | 2003-07-31 | 2005-05-26 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20090297611A1 (en) * | 2003-07-31 | 2009-12-03 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20090285900A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050043282A1 (en) * | 2003-07-31 | 2005-02-24 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20110209699A1 (en) * | 2003-07-31 | 2011-09-01 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026879A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20090317476A1 (en) * | 2003-07-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| FR2861077B1 (fr) * | 2003-10-20 | 2006-03-03 | Aventis Pharma Sa | Formes cristallines du chlorydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol |
| JP2007509050A (ja) * | 2003-10-20 | 2007-04-12 | インフラジム ファーマシューティカルズ リミテッド | ３β−アミノ−１７−メチレンアンドロスタン−６α，７β−ジオール塩酸塩の結晶形 |
| US20080051382A1 (en) * | 2003-10-20 | 2008-02-28 | Inflazyme Pharmaceuticals Ltd. | Crystalline Forms of 3-Beta-Amino 17-Methylene Androstane-6-Alpha 7-Beta-Diol Hydrochloride |
| US20050227927A1 (en) * | 2004-03-31 | 2005-10-13 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| US20050222049A1 (en) * | 2004-03-31 | 2005-10-06 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| US20090317477A1 (en) * | 2004-03-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| CA2706440C (en) * | 2007-11-21 | 2014-03-25 | The Procter & Gamble Company | Preparations, methods and kits useful for treatment of cough |
| JP5655243B2 (ja) * | 2009-10-19 | 2015-01-21 | 国立大学法人 熊本大学 | インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤 |
| AU2011206864B2 (en) | 2010-01-15 | 2013-12-19 | Suzhou Neupharma Co., Ltd. | Certain chemical entities, compositions, and methods |
| CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
| EP3453714B1 (en) | 2011-02-02 | 2020-11-04 | Suzhou Neupharma Co., Ltd | Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof |
| EP3453713B1 (en) * | 2012-04-29 | 2021-09-08 | Neupharma, Inc. | Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer |
| TW201427685A (zh) | 2012-09-25 | 2014-07-16 | Biogen Idec Inc | Ｆｉｘ多肽的應用 |
| KR20150130426A (ko) | 2013-03-14 | 2015-11-23 | 에퀴녹스 파머수티칼스 (캐나다) 인코포레이티드 | Ship1 조절제 및 그와 관련된 방법 |
| JP6407951B2 (ja) | 2013-03-14 | 2018-10-17 | アクイノックス ファーマシューティカルズ （カナダ） インコーポレイテッド | Ｓｈｉｐ１モジュレーターおよびそれに関連する組成物および方法 |
| TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| CN104744547B (zh) * | 2013-12-27 | 2017-02-15 | 天津医科大学 | 一种抗乳腺癌转移作用的孕甾烷生物碱衍生物及医药用途 |
| US9944590B2 (en) | 2015-06-26 | 2018-04-17 | Aquinox Pharmaceuticals (Canada) Inc. | Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol |
| WO2017127753A1 (en) | 2016-01-20 | 2017-07-27 | Aquinox Pharmaceuticals (Canada) Inc. | Synthesis of a substituted indene derivative |
| ES2960542T3 (es) * | 2018-04-06 | 2024-03-05 | Taro Pharmaceuticals Inc | Derivados de hexadecahidro-1H-ciclopenta[a]fenantreno útiles en el tratamiento del dolor y la inflamación |
| EP3774738A1 (en) | 2018-04-06 | 2021-02-17 | Aquinox Pharmaceuticals (Canada) Inc. | Indene derivatives useful in treating pain and inflammation |
| EP3774746A1 (en) | 2018-04-06 | 2021-02-17 | Aquinox Pharmaceuticals (Canada) Inc. | Indene derivatives useful in treating pain and inflammation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3682983A (en) * | 1969-11-12 | 1972-08-08 | Klaus Prezewowsky | Preparation of {66 {11 {11 -17 ethinyl steroids |
| ATE188036T1 (de) | 1990-01-18 | 2000-01-15 | Cura Nominees Pty Ltd | Glykoalkaloide |
| US5877185A (en) | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| CA2086221C (en) * | 1992-12-23 | 2003-07-15 | Raymond J. Andersen | Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent |
| EP0688333B1 (en) | 1993-03-10 | 1998-08-19 | Magainin Pharmaceuticals Inc. | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| US5817632A (en) | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| AU5426596A (en) | 1995-05-16 | 1996-11-29 | Salk Institute For Biological Studies, The | Modulators for new members of the steroid/thyroid superfamily of receptors |
| US5874597A (en) * | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
| US6060465A (en) * | 1997-02-06 | 2000-05-09 | Miljkovic; Dusan | Bile acids and their derivatives as glycoregulatory agents |
| CN100398109C (zh) | 1998-03-06 | 2008-07-02 | 杨伯翰大学 | 甾族化合物衍生的抗生素 |
| DZ3355A1 (fr) * | 2000-04-28 | 2001-11-08 | Inflazyme Pharm Ltd | Steroides 3-azote-6,7-dioxyde et les emplois qui s'y rapportent |
-
2001
- 2001-04-30 DZ DZ013355A patent/DZ3355A1/fr active
- 2001-04-30 AU AU5208401A patent/AU5208401A/xx active Pending
- 2001-04-30 RU RU2002131941/04A patent/RU2291873C2/ru not_active IP Right Cessation
- 2001-04-30 US US09/845,775 patent/US6635629B2/en not_active Expired - Fee Related
- 2001-04-30 PL PL01365798A patent/PL365798A1/xx not_active Application Discontinuation
- 2001-04-30 UA UA2002119460A patent/UA79229C2/uk unknown
- 2001-04-30 DK DK01925262T patent/DK1278763T3/da active
- 2001-04-30 ES ES01925262T patent/ES2282247T3/es not_active Expired - Lifetime
- 2001-04-30 BR BR0110419-5A patent/BR0110419A/pt not_active IP Right Cessation
- 2001-04-30 AU AU2001252084A patent/AU2001252084B2/en not_active Ceased
- 2001-04-30 PT PT01925262T patent/PT1278763E/pt unknown
- 2001-04-30 CN CNB018101674A patent/CN1214039C/zh not_active Expired - Fee Related
- 2001-04-30 DE DE60126597T patent/DE60126597T2/de not_active Expired - Lifetime
- 2001-04-30 YU YU88102A patent/YU88102A/sh unknown
- 2001-04-30 NZ NZ522181A patent/NZ522181A/en unknown
- 2001-04-30 JP JP2001580936A patent/JP2003531916A/ja active Pending
- 2001-04-30 WO PCT/CA2001/000581 patent/WO2001083512A1/en active IP Right Grant
- 2001-04-30 MX MXPA02010645A patent/MXPA02010645A/es active IP Right Grant
- 2001-04-30 US US10/258,950 patent/US20040034216A1/en not_active Abandoned
- 2001-04-30 AP APAP/P/2002/002659A patent/AP1825A/en active
- 2001-04-30 EP EP01925262A patent/EP1278763B1/en not_active Expired - Lifetime
- 2001-04-30 SK SK1569-2002A patent/SK15692002A3/sk unknown
- 2001-04-30 OA OA1200200328A patent/OA12255A/en unknown
- 2001-04-30 CA CA002418748A patent/CA2418748A1/en not_active Abandoned
- 2001-04-30 HU HU0300908A patent/HUP0300908A2/hu unknown
- 2001-04-30 AT AT01925262T patent/ATE353909T1/de not_active IP Right Cessation
- 2001-04-30 IL IL15244801A patent/IL152448A0/xx active IP Right Grant
- 2001-04-30 KR KR1020027014524A patent/KR20030045671A/ko not_active Application Discontinuation
- 2001-04-30 EE EEP200200613A patent/EE200200613A/xx unknown
-
2002
- 2002-10-24 NO NO20025106A patent/NO324873B1/no unknown
- 2002-10-24 IL IL152448A patent/IL152448A/en not_active IP Right Cessation
- 2002-10-24 ZA ZA200208631A patent/ZA200208631B/en unknown
- 2002-11-19 BG BG107289A patent/BG107289A/bg unknown
- 2002-11-20 MA MA26916A patent/MA25808A1/fr unknown
- 2002-11-22 CO CO02106292A patent/CO5590904A2/es not_active Application Discontinuation
- 2002-11-28 HR HR20020944A patent/HRP20020944A2/xx not_active Application Discontinuation
-
2003
- 2003-04-28 HK HK03102993A patent/HK1050694A1/xx not_active IP Right Cessation
- 2003-07-21 US US10/624,946 patent/US7112580B2/en not_active Expired - Fee Related
-
2006
- 2006-07-28 US US11/496,052 patent/US20070060553A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5590904A2 (es) | Esteriodes 3-nitrogen-6,7-dioxigeno y usos relacionados con este | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| PA8494101A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
| PE20080688A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion | |
| ES2196328T3 (es) | Derivados de tetrahidrofurano tetraciclicos sustituidos. | |
| AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
| AR040030A1 (es) | Moduladores biciclicos de la funcion del receptor de androgeno | |
| AR035775A1 (es) | Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| ECSP109932A (es) | Compuestos de biciclolactama sustituida | |
| SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR024918A1 (es) | Derivados de ciclobuteno, su preparacion y sus usos terapeuticos. | |
| GT200300108A (es) | Derivados de benzoxazina y usos de los mismos | |
| RS20050692A (en) | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | |
| UY27232A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| PE20060288A1 (es) | Derivados de fenilaminopropanol | |
| CO4290299A1 (es) | Derivados de 1,5-benzodiazepina | |
| SV2002000026A (es) | 2-aminopiridinas que contiemen sustituyentes de tipo anillo condensado ref. pc10493 | |
| AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
| PE20030611A1 (es) | Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones | |
| HUP0400546A2 (hu) | Antiangiogén hatású triciklusos indolszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| PA8561201A1 (es) | Farmacos biotransformables en d-prolinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |